Question 1

What is Revvity's P/FCF ratio?

Accepted Answer

Revvity (RVTY) P/FCF ratio is 25.0× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month free cash flow, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/FCF ratio calculated?

Accepted Answer

P/FCF = Market Capitalisation ÷ Trailing Twelve-Month (TTM) Free Cash Flow, where Free Cash Flow = Operating Cash Flow − Capital Expenditures. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/FCF ratio?

Accepted Answer

The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.

Question 4

What is a good P/FCF ratio for Revvity?

Accepted Answer

Mature companies that consistently convert profit into cash often trade at 15–25× P/FCF; capital-intensive businesses with lumpy capex typically trade lower. Compare against sector peers and against the company's own multi-year average — single-year P/FCF can be distorted by working-capital swings. For Revvity specifically, the relevant sector benchmark is the current sector median of 19.1×.

Question 5

Is Revvity's P/FCF ratio high or low?

Accepted Answer

Revvity's P/FCF ratio of 25.0× is below its own 5-year average of 112.2× and above the sector median of 19.1×. That places the current reading at the 62th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Revvity's historical P/FCF ratio range?

Accepted Answer

In the available daily series, Revvity (RVTY) P/FCF ratio has ranged from a low of 8.5× in 2009 to a high of 1391.8× in 2024. The 5-year average is 112.2× and the 5-year median is 21.5×.

Question 7

What was Revvity's P/FCF ratio in 2025?

Accepted Answer

Revvity (RVTY) P/FCF ratio at the end of 2025 was 21.5×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month free cash flow figure available at that date.

Question 8

Why does Revvity's P/FCF ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (free cash flow). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$11B	$511M	21.5×	—	Dec 28, 2025
2024	$13.6B	—	—	—	Dec 29, 2024
2023	$13.5B	$9.9M	1362.2×	—	Dec 31, 2023
2022	—	—	—	—	Dec 31, 2022
2021	$25.4B	$1.32B	19.2×	-0.5×	Dec 31, 2021
2020	$16.1B	$815M	19.7×	-18.5×	Dec 31, 2020
2019	$10.8B	$282M	38.2×	-1.6×	Dec 31, 2019
2018	$8.69B	$218M	39.9×	+7.3×	Dec 31, 2018
2017	$8.13B	$249M	32.6×	+14.6×	Dec 31, 2017
2016	$5.73B	$318M	18.0×	-5.3×	Dec 31, 2016
2015	$6B	$257M	23.3×	+3.8×	Dec 31, 2015
2014	$4.92B	$253M	19.5×	-19.3×	Dec 31, 2014
2013	$4.64B	$120M	38.8×	+5.6×	Dec 31, 2013
2012	$3.65B	$110M	33.3×	+21.6×	Dec 31, 2012
2011	$2.26B	$194M	11.6×	-11.5×	Dec 31, 2011
2010	$3.02B	$131M	23.2×	+2.7×	Dec 31, 2010
2009	$2.39B	$117M	20.5×	+11.1×	Dec 31, 2009
2008	$1.64B	$175M	9.4×	-10.1×	Dec 31, 2008
2007	$3.09B	$158M	19.5×	-13.9×	Dec 31, 2007
2006	$2.77B	$83M	33.4×	+16.7×	Dec 31, 2006
2005	$3.05B	$183M	16.7×	+0.8×	Dec 31, 2005
2004	$2.88B	$182M	15.8×	+1.5×	Dec 31, 2004
2003	$2.15B	$150M	14.4×	-16.4×	Dec 31, 2003
2002	$1.04B	$33.7M	30.8×	—	Dec 31, 2002


McKesson (MCK)	17.8×
Gilead Sciences (GILD)	16.9×
DexCom (DXCM)	16.9×
Pfizer (PFE)	16.7×
Humana (HUM)	16.4×
Quest Diagnostics (DGX)	16.3×
UnitedHealth Group (UNH)	15.9×
Labcorp Holdings (LH)	15.9×
Becton, Dickinson and (BDX)	14.0×
HCA Healthcare (HCA)	13.5×
Elevance Health (ELV)	13.4×
Incyte (INCY)	12.9×
CVS Health (CVS)	12.4×
Universal Health Services (UHS)	12.2×
Baxter International (BAX)	12.1×
Cardinal Health (CAH)	11.3×
IQVIA (IQV)	11.3×
Bristol-Myers Squibb (BMY)	10.4×
Biogen (BIIB)	10.3×
Zimmer Biomet Holdings (ZBH)	9.6×
Cigna (CI)	9.1×
Viatris (VTRS)	9.1×
DaVita (DVA)	6.9×
Teladoc Health (TDOC)	3.9×
Centene (CNC)	2.5×

P/FCF Ratio for Revvity (RVTY) 2002-2026

P/FCF Ratio daily chart for Revvity (RVTY)

Historical P/FCF Ratio for Revvity (RVTY) from 2002 to 2025

About P/FCF Ratio at Revvity (RVTY)

Revvity P/FCF Ratio by Year

Revvity P/FCF Ratio 2025: 21.5×

Revvity P/FCF Ratio 2023: 1362.2×

Revvity P/FCF Ratio 2021: 19.2×

Revvity P/FCF Ratio 2020: 19.7×

Revvity P/FCF Ratio 2019: 38.2×

Sector peers by P/FCF Ratio — chart

Sector peers by P/FCF Ratio — table

Frequently asked questions

Revvity (RVTY) Key Financials